ALXO vs. AUPH, IRON, NRIX, SVRA, PRAX, PRTC, ELVN, TYRA, PHAR, and TNGX
Should you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Aurinia Pharmaceuticals (AUPH), Disc Medicine (IRON), Nurix Therapeutics (NRIX), Savara (SVRA), Praxis Precision Medicines (PRAX), PureTech Health (PRTC), Enliven Therapeutics (ELVN), Tyra Biosciences (TYRA), Pharming Group (PHAR), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical preparations" industry.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Aurinia Pharmaceuticals received 526 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 73.03% of users gave Aurinia Pharmaceuticals an outperform vote while only 61.54% of users gave ALX Oncology an outperform vote.
In the previous week, ALX Oncology had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for ALX Oncology and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.52 beat ALX Oncology's score of -0.02 indicating that ALX Oncology is being referred to more favorably in the news media.
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 50.3% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Aurinia Pharmaceuticals has higher revenue and earnings than ALX Oncology. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
Aurinia Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 102.43%. ALX Oncology has a consensus price target of $18.83, suggesting a potential upside of 11.64%. Given ALX Oncology's higher possible upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than ALX Oncology.
ALX Oncology has a net margin of 0.00% compared to ALX Oncology's net margin of -44.45%. ALX Oncology's return on equity of -20.10% beat Aurinia Pharmaceuticals' return on equity.
Summary
ALX Oncology beats Aurinia Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get ALX Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ALX Oncology Competitors List
Related Companies and Tools
